The emergence of long COVID has fundamentally challenged our understanding of post-viral recovery, with the global patient population surging from 60 million to an estimated 400 million between 2020 and 2024. As the medical community grapples with this scale, Biopharma expert Ivan Kairatov brings a
The persistent challenge of treating Non-Small Cell Lung Cancer remains a critical hurdle in modern oncology because malignant cells frequently develop a robust resistance to standard chemical interventions. While approximately 80 to 85 percent of all lung cancer diagnoses fall into this specific
The pharmaceutical industry is currently facing a transformative and deeply sobering moment in immunology following the sudden, high-profile termination of a once-promising clinical drug program. For years, the OX40 receptor—a potent costimulatory molecule on T-cells—was hailed as the next frontier
Ivan Kairatov is a distinguished biopharma expert with a career built on navigating the intricate crossroads of biotechnology innovation and regulatory strategy. With extensive experience in research and development, he has spent years analyzing how emerging therapies transition from the laboratory
The biotechnology sector often operates on a knife-edge where a single clinical observation can evaporate years of progress and hundreds of millions of dollars in venture capital overnight. Aardvark Therapeutics recently experienced this volatility firsthand when it announced a voluntary suspension
Navigating the High Stakes of Roche’s Latest MS Breakthrough The pharmaceutical industry currently watches with bated breath as Roche’s fenebrutinib, a drug once hailed as the potential gold standard for oral multiple sclerosis (MS) therapy, hits a wall of regulatory uncertainty. While the clinical
